The short version: I'm giving LEO-24 3 out of 10. Their lab reports are genuine and checkable, and that deserves credit. Their guides are where it falls apart: wrong storage advice, no sources, no side effects, and dose plans for weight loss on products their own footer says are “not for human consumption”. That last one is why there's a warning on the grade.
What I looked at: LEO-24's website, all 3 of their guides, 8 product pages in full (plus a scan of all 69), their FAQ, terms, returns and privacy pages, and 9 of their lab report pages, 5 of which I checked on the lab's own site. All on 14 October 2026.
The score, broken down
| What I marked | Score | Why |
|---|---|---|
| Is it clear? | 1 / 2 | Tidy step lists and tables, but the storage advice contradicts itself between pages. |
| Is it useful? | 1 / 2 | The mixing maths is handy. But there are only 3 guides, all “how to dose”, and the product pages are sales copy. |
| Are the facts right? | 1 / 2 | Some match the official labels. The fridge temperature, injection interval and how long a mixed vial lasts don't. |
| Does it show the evidence? | 0 / 2 | Not one source, trial name or study number in any guide. |
| Is it honest about downsides? | 0 / 2 | No side effect is named anywhere, and retatrutide's unapproved status is never mentioned. |
| Total | 3 / 10 | Honest testing, careless guides. |
The supplier checks
| Check | Result | Why |
|---|---|---|
| Lab reports | Amber | Named lab, batch numbers, dates and working verify links. But the newest test is a year old, some report pages are mislabelled, and the vials tested well over the label amount. |
| Claims & dosing | Red | “Research use only” in the footer, but a weight-loss dose plan in the guides, insulin syringes in every kit, and a product page about cancer therapy and hepatitis. |
| Basics | Amber | Email and a returns policy, but no phone, no company registration number, two different addresses and an unfinished privacy policy. |
What LEO-24 got right
Their lab reports are real, and you can check them. Each report names the lab (Janoshik), gives a batch number and test dates, and links to the lab's own site. I opened five of those links: tirzepatide, retatrutide, semaglutide, a semaglutide heavy-metals test and BPC-157. All five matched the numbers LEO-24 publishes. Plenty of shops say “third-party tested” and show nothing. LEO-24 shows its working, and that's the main reason this isn't lower.
The mixing maths adds up. Their tables converting a vial and a volume of water into a concentration are correct. Small thing, but people get this wrong all the time.
What dragged it down
A fridge at room temperature. Two of their three guides say to keep the vial in the fridge at 20 to 25°C, both before and after mixing. That's room temperature. A fridge runs at 2 to 8°C, which is what the official tirzepatide label says, and what LEO-24's own product pages and semaglutide guide say too. Someone following the guide could leave a vial out in a warm kitchen thinking they're doing it right.
“Before mixing: Store in the refrigerator at 20–25°C”
“Not for human consumption”, next to a weight-loss plan. Every page footer says their products are for research only and “not for human consumption”. Then the retatrutide guide gives a “Suggested Protocol (for weight loss)”, a four-step weekly dose ladder. The FAQ says every vial ships with insulin syringes. And the Thymosin Alpha-1 page talks about cancer therapy and hepatitis. You can't have it both ways. I'm not repeating their doses here, and you shouldn't take dosing advice from a shop.
“Suggested Protocol (for weight loss):”
No sources, no side effects. None of the three guides cites a trial, a paper or a label. None names a single side effect. The retatrutide guide never says the drug isn't approved anywhere. Its published phase 2 trial found stomach and gut side effects that rose with the dose, and a faster heart rate that peaked around week 24. Their dose ladder doesn't match the doses used in that trial either. A buyer reading only LEO-24 would know none of this.
Smaller facts that don't hold up. The semaglutide guide says to inject every 5 to 6 days, but the approved medicine is once a week and lasts about a week in the body. The guides say a mixed vial is good for 45 days, where standard injection-safety guidance is 28 days once a vial is opened, and the approved tirzepatide vial says 30.
The lab reports, side by side.
| What they say | What I found | What good looks like |
|---|---|---|
| Tested by Janoshik, with verify links | True. Named lab, batch numbers, dates, and 5 of 5 links I opened match. Ref E1. | Exactly this. Credit where it's due. |
| “Excellent labeling accuracy” | The vials tested 16 to 23% over the label: 5.79 mg in a 5 mg semaglutide vial, 11.61 mg in a 10 mg retatrutide vial, 6.13 mg in a 5 mg BPC-157 vial. Their mixing tables assume the label amount. Ref E7. | Content close to the label, or the real amount printed so the maths matches what's in the vial. |
| “Each batch tested” | The newest report is from October 2025, a year old. One strength per product, nothing for CagriSema. Ref E1. | A current report for the batch you're actually buying. |
| Report pages | Mix-ups, like a semaglutide heavy-metals page that says “Sample: KPV 10mg”. The lab itself shows the right sample. Ref E8. | Pages that match the report they're showing. |
The basics. There's an email and a returns policy, but no phone number and no company registration number. The contact page and the footer give two different Sandton addresses. The returns rules differ across three pages. And the privacy policy ends with “Effective Date: [Insert Date]”, a template nobody finished. Ref E9.
What would get them a better grade
- Fix the fridge temperature to 2 to 8°C everywhere.
- Take dose plans and weight-loss protocols off a research-use shop, or stop calling it research use.
- Name the side effects the trials found, and say plainly what's approved and what isn't.
- Cite sources for every number.
- Publish current lab reports for the batches on sale, with the real measured amount.
- One address, a phone number, a registration number, and a finished privacy policy.
Do that and I'll grade it again, here, in public.
Corrections
Spotted something I got wrong? Tell me. I fix facts fast and say what changed. I don't change a grade because someone complains, only when I've got a fact wrong or the supplier changes what they publish.
Evidence log
| Ref | What they said | Where | Seen |
|---|---|---|---|
| E1 | Janoshik reports with batch numbers, dates and verify links; newest October 2025 | tests index · saved | 14 Oct 2026 |
| E2 | “Store in the refrigerator at 20–25°C” | tirzepatide guide · saved | 14 Oct 2026 |
| E3 | “store the vial in a refrigerator between 20°C and 25°C” | retatrutide guide · saved | 14 Oct 2026 |
| E4 | “Suggested Protocol (for weight loss):” | retatrutide guide · saved | 14 Oct 2026 |
| E5 | “4 insulin syringes, and 4 alcohol swabs” with each vial | FAQ | 14 Oct 2026 |
| E6 | “adjunct treatment in cancer therapy”; “Hepatitis B and C” | Thymosin Alpha-1 · saved | 14 Oct 2026 |
| E7 | “The measured mass of 5.79 mg demonstrates excellent labeling accuracy” | semaglutide test · saved | 14 Oct 2026 |
| E8 | “Sample: KPV 10mg” on a semaglutide heavy-metals page | test 81942 · saved | 14 Oct 2026 |
| E9 | “Effective Date: [Insert Date]” | privacy policy · saved | 14 Oct 2026 |
Update log
- 14 Oct 2026: First published.
Sources
- Zepbound (tirzepatide) US prescribing information and instructions for use, DailyMed.
- Wegovy (semaglutide) US prescribing information, DailyMed.
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM, 2023.
- CDC: injection safety, multi-dose vials.
- Drugs.com: retatrutide approval status.
